Gene therapy company developing AAV-based therapies for highly prevalent chronic diseases, including geographic atrophy, thyroid eye disease, and type 1 diabetes. Bicoastal since founding, with gene-therapy manufacturing and process development anchored in RTP and a Palo Alto office. Raised $320M Series D in September 2025, one of the largest NC life-sciences rounds of the year.
At a glance
- Founded: 2019
- HQ: Durham
- Sector: Biotech
- Stage: Growth
- Total raised: $770.5M
- Last round: Growth
Where the team studied
Filter the directory by schoolDuke University
- Roger JeffsAlumChemistrySource
University of North Carolina at Chapel Hill
- Roger JeffsAlumPh.D., PharmacologySource
Each line was checked against a primary source. Founder education is recorded for part of the directory, so a name missing here is a gap in what has been checked, not a statement that they studied somewhere else. Tell me what is missing.
The rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.